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ABSTRACT
Herpes simplex virus (HSV) type 1 affects a majority of the population
and recent evidence suggests involvement in Alzheimer’s disease
aetiology. We investigated the prevalence of HSV type 1 and 2 in the
Tampere Autopsy Study (TASTY) brain samples using PCR and
sero-positivity in plasma, and associations with Alzheimer’s disease
neuropathology. HSV was shown to be present in human brain
tissue in 11/584 (1.9%) of samples in the TASTY cohort, of which six
had Alzheimer’s disease neuropathological amyloid beta (Aβ)
aggregations. Additionally, serological data revealed 86% of serum
samples tested were IgG-positive for HSV. In conclusion, we report
epidemiological evidence of the presence of HSV in brain tissue free
from encephalitis symptoms in a cohort most closely representing the
general population (a minimum prevalence of 1.9%). Whereas 6/11
samples with HSVDNA in the brain tissue had Aβ aggregations, most
of those with Aβ aggregations did not have HSV present in the brain
tissue.
KEY WORDS: Herpes simplex virus, Amyloid beta aggregations,
Alzheimer’s disease, PCR detection, Human brain tissue,
Paraffin-embedded samples
INTRODUCTION
Herpes simplex virus type 1 (HSV1) affects a majority of the
population, in some cohorts up to 90% (Lövheim et al., 2015b;
Smith and Robinson, 2002). The disease appears as cold sores,
typically seen on the lips or face, with primary infection usually
during childhood. HSV type 2 (HSV2) predominantly affects the
genital area and is one of the most common sexually transmitted
infections. The virus remains latent in neuronal cell bodies and
reactivates due to stress, illness and other unknown factors
throughout an individual’s life. In some cases, individuals can
develop adverse reactions such as herpes simplex encephalitis
(HSE), a life-threatening disease (Whitley and Roizman, 2001).
Alzheimer’s disease (AD) is the most common form of dementia
and growing elderly populations will continue to put pressure on
health systems to alleviate this devastating disease, which currently
has no cure (Jellinger, 2006). The disease is characterised by
progressive dementia, culminating in neuronal loss thought to be
caused by the two main hallmarks of the disease – amyloid beta
(Aβ) aggregations and neurofibrillary tangles (NFT) (Goate and
Hardy, 2012).
The most common and strongest genetic risk factor for AD is the
apolipoprotein E (APOE) epsilon 4 allele, which increases the risk
of developing AD approximately threefold in heterozygotes and
even more among homozygotes (Corder et al., 1995; Farrer et al.,
1997; van Duijn et al., 1994). This gene can also facilitate infection
with HSV (Bhattacharjee et al., 2008; Burgos et al., 2006, 2003). In
addition, the rare HSE affects similar brain regions to those seen in
AD (Ball, 1982). In recent years, evidence for HSV as a possible
cause of AD has accumulated, and is supported by epidemiological
(Letenneur et al., 2008; Lövheim et al., 2015a,b), neuropathological
(Steel and Eslick, 2015; Wozniak et al., 2009), as well as in vitro
data demonstrating AD-specific changes in neural cells following
HSV infection (Santana et al., 2012).
We investigated the prevalence of HSV in 584 brain tissue samples
from Tampere Autopsy Study (TASTY) cohort of 603 individuals,
primarily without dementia, to assess the virus’ ability to gain access
to the brain without causing noticeable symptoms such as HSE. In
addition, we investigated whether the presence of HSV in the brain
had any effect on the presence of the neuropathology associated with
AD in this cohort of community-dwelling individuals primarily free
from dementia.
RESULTS
PCR detection of HSV brain tissue positivity
DNA was extracted from 584 paraffin-embedded brain samples from
the TASTY cohort, comprising pooled middle frontal gyrus, gyrus
cinguli with corpus callosum, hippocampus and cerebellum, to test for
the presence of HSV genomic material. Total amount of extracted
DNA for individual samples, as assessed by spectrophotometry,
ranged from 1.8-57.0 µg. As the spectrophotometric value does not
differentiate between intact and degraded DNA, we employed a
qPCR-based assay designed to determine, in absolute numbers,
each sample’s content of a 41 bp target within a conserved single-
copy locus in the human genome. All samples were quantified
against the 41 bp target reaction and numbers of gene copies/sample
were found to range from 1.2×105-48.6×105. Samples had similar
human gene copies/reaction whether positive for the presence of
HSV (n=11, containing 1.2×105-20.2×105 copies; mean 10.6×105),
or negative (n=573, containing 1.2×105-48.5×105 copies; mean
14.7×105) (P=0.127). All HSV1- or HSV2-positive samples were
also quantified by means of a 129 bp target within the same
conserved single-copy locus in the human genome, and calculating
the ratio of 129/41 bp gene copies allowed for further assessment of
DNA quality; as DNA fragmentation destroys longer templates at a
higher rate than shorter ones, this value declines as DNA quality
decreases. The 11 HSV-positive samples scored 4.5-21.0% (mean
12.6%) compared with a range of 2.4-15.5% (mean 7.8%) for 24
randomly selected negative samples (P=0.039).Received 21 June 2016; Accepted 20 September 2016
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PCR reactions directed against 62-73 bp sections of the
HSV1 and HSV2 genomes were used to detect the respective
viral DNA in the brain tissue samples. HSV1 PCR reactions targeted
theUS5,UL5, andUL27 genes; HSV2 PCR reactions targetedUS4,
UL5 and UL29. In the trade-off between maximal sensitivity on the
one hand and high standards of specificity and reproducibility on the
other, no Ct cut-off value was employed, and only samples positive
for at least two of the PCR reactions were scored positive. The
independent PCR reactions thereby confirm each other (Mahony
et al., 1993). Of 584 analysed samples, 10 were positive for HSV1,
whereas one was positive for HSV2 (positivity in US4 and UL29,
but not UL5 PCR reactions). None were positive for both HSV1
and HSV2.
In detecting HSV1 DNA, theUS5,UL5 andUL27 PCR reactions
were positive in 18 (3.1%), 16 (2.7%) and 19 (3.3%) out of 584
analysed cases, respectively. There were 27 cases (4.6%) with only
one positive reaction, and 10 (1.7%) where at least two reactions
were positive. Six out of these 10 were triple-positive. Mean Ct
values were 38.0±2.7 (±s.d.) for cases with at least two positive
reactions compared with 39.4±1.0 for those with only one positive
reaction (P=0.156). These Ct values are high, indicating sub-
optimal qPCR conditions, probably due to the presence of inhibitory
substances. However, agarose-gel electrophoresis staining showed
unambiguous correlation between a positive qPCR score and the
presence of a product band of correct size (data not shown). The
correlations between positivity of the different PCR reactions were
0.395 (US5 to UL5), 0.383 (UL5 to UL27) and 0.414 (UL5 to
UL27), respectively (P<0.001 for all correlations). In the following
analyses, the HSV1 and HSV2 PCR data are pooled (see Table 1 for
HSV DNA-positive case characteristics).
HSV brain tissue positivity
Cases (n=10 HSV1 and 1 HSV2, total of n=11 HSV-positive) who
had at least two positive PCR reactions were regarded as HSV
DNA-positive in brain tissue (11/584=1.9%). Age, sex and
APOEε4 carriership (P=0.413, P=0.754 and P=0.746,
respectively) did not affect the risk of being HSV DNA-positive.
Individuals were aged 60 years and over in 59% of the cases
(n=346), of which 2.0% (7/346) had a prevalence of HSV positivity
in brain tissue. The proportion of cases with Aβ aggregations
(Fig. 1) was 6/11 (54.5%) among those positive for HSV DNA in
brain tissue compared with 160/530 (30.2%) among those negative
for HSV DNA (Fisher’s exact test, P=0.101 of cases with available
Aβ aggregation data), and for NFT, 5/9 (55.6%) compared with 194/
465 (41.7%) (Fisher’s exact test, P=0.502 of cases with NFT data).
The proportion of cases with both Aβ aggregations and NFTwas 4/9
(44.4%) among HSV DNA-positive cases compared with 81/451
(18.0%) (Fisher’s exact test, P=0.097 of cases with complete Aβ
aggregation and NFT neuropathology data). Six cases of the
TASTY cohort had been diagnosed with AD while alive, of which
one individual was positive for HSV DNA in brain tissue. The
proportion of individuals with HSV DNA positivity was 1/6
(16.7%) among those with AD, compared with 10/551 (1.8%) of
non-demented cases (Fisher’s exact test, P=0.113 of cases with
documented dementia information).
Serology
It was possible to obtain serology data for 141 of the cases (24.1%),
of which 121 (85.8%) were positive for anti-HSV IgG. Mean age
was 57.6±15.3 for anti-HSV-IgG-negative cases and 64.5±17.5 for
those anti-HSV-IgG-positive (P=0.103). Sex and APOEε4
carriership did not impact on the risk of carrying HSV; 74/88
(84.1%) of the men and 47/53 (88.7%) of the women were anti-
HSV-positive (P=0.449), and 45/53 (84.9%) of the APOEε4
carriers compared with 76/88 (86.4%) of those not carrying an
APOEε4 allele (P=0.810).
Serology and neuropathology
Among anti-HSV-IgG-positive cases for which Aβ aggregation data
was available, 36/111 (32.4%) were Aβ-aggregation-positive
compared with 2/19 (10.5%) of those anti-HSV-IgG-negative [χ2:
P=0.052; adjusted for age in a binary logistic regression: odds ratio
(OR) 2.771, 95% confidence interval (CI) 0.567–13.541, P=0.208].
NFT was seen among 30/77 (39.0% of anti-HSV-IgG-positive)
compared with 3/12 (25.0% of anti-HSV-IgG-negative) with NFT
neuropathology data in this cohort (χ2: P=0.352; age-adjusted: OR
1.264, CI 0.281–5.681, P=0.760).
IgM and IgG serology
There were 15/141 (2.5%) anti-HSV-IgM-positive. All but one of
them were also anti-HSV-IgG-positive and hence regarded as
reactivated infections. One 58-year-old male was IgM-positive and
IgG-negative, which indicates primary infection. The individual
had no Aβ aggregations or NFT. Among those positive for anti-HSV
IgG, those who were also positive for anti-HSV IgM were younger
(55.3±16.7 versus 65.6±17.3, P=0.038) and more often male [12/74
(16.2%) versus 2/47 (4.3%), P=0.045]. Anti-HSV IgM antibodies
were equally common among those with or without an APOEε4
Table 1. Cases from the Tampere Autopsy Study that were positive for HSV DNA
Case # Age Sex APOE Aβ %
Plaque
subtype CERAD* NFT/1 mm2 Dementia
HSV1
positive‡
HSV2
positive‡
HSV
IgG
HSV
IgM CoD_class
165 43 Male e3/e3 0 None No Aβ ND None 1 0 Neg Neg Suicide
174 82 Male e3/e3 0 None No Aβ ND None 1 0 92 Neg Disease (cancer)
226 78 Female e4/e3 1.1 ND Moderate Aβ 5.6 AD 0 1 Neg Neg Accident
270 74 Male e3/e3 0.8 Classic Frequent Aβ 4.8 None 1 0 ND ND Disease (heart disease)
411 72 Male e4/e4 0 None No Aβ 0 None 1 0 ND ND Disease (infectious, not HSE)
415 50 Male e3/e3 0 None No Aβ 3.2 None 1 0 ND ND Disease (heart disease)
452 89 Female e3/e3 0 None No Aβ 0 None 1 0 ND ND Accident
459 78 Female e3/e2 0.4 Primitive Sparse Aβ 0 None 1 0 ND ND Disease (stroke)
504 59 Male e3/e4 1 Classic Moderate Aβ 13.6 None 1 0 ND ND Disease (heart disease)
513 57 Male e3/e3 0.3 Primitive Sparse Aβ 0 None 1 0 ND ND Disease (infectious, not HSE)
561 68 Male e3/e4 1.3 Classic Moderate Aβ 14.4 None 1 0 ND ND Disease (heart disease)
*Density of Aβ aggregations
‡ Positive result from two HSV PCR reactions
AD, Alzheimer’s disease; CERAD, Consortium to Establish A Registry for Alzheimer’s Disease, CoD, cause of death; HSE, Herpes simplex encephalitis; ND, no
data; Neg, negative
1350
RESEARCH ARTICLE Disease Models & Mechanisms (2016) 9, 1349-1355 doi:10.1242/dmm.026674
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
allele [6/45 (13.3%) versus 8/76 (10.5%), P=0.641]. Adjusted for
age and sex, there were no significant relations between anti-HSV
IgM and Aβ aggregations or NFT (P=0.346 and P=0.519,
respectively).
Serological levels and correlations
Anti-HSV IgG level (among those anti-HSV-IgG-positive) was
affected by age and sex of the cases (multiple linear regression: age
β=0.298, P=0.018, male sex β=11.563, P=0.011). The level was
81.8±23.0 among those who carried at least one APOEε4 allele
compared with 74.2±22.6 among those who did not (P=0.079).
There were no significant correlations between anti-HSV IgG level
and Aβ-immunoreactivity (IR) percentage and NFT count (Pearson
correlation −0.002, P=0.987 and –0.039, P=0.734, respectively).
Serology and PCR positivity
Blood plasma was available for only three of the HSV-DNA-
positive samples. Interestingly, two out of these three cases – one
HSV1-positive and the single HSV2-positive – were negative for
anti-HSV IgG, compared with 120/138 (87.0%) of those HSV-
DNA-negative with available serological data (Fisher’s exact test
P=0.053).
DISCUSSION
Our main finding was that in an unhospitalised cohort (see Fig. 2) of
603 individuals primarily without dementia, we detected HSV in
brain tissue of 11 (1.9%) of the 584 cases fromwhich it was possible
to extract DNA. Our serological analyses of 141 cases revealed
85.8% carrying HSV, which is slightly lower than – although in line
with – previous epidemiological studies of the virus’ presence
(Lövheim et al., 2015a,b; Smith and Robinson, 2002).
We used strict criteria for positivity, possibly underestimating the
actual number because of sample degradation. Preparations from
FFPE brain tissue generally yield more severely degraded DNA
than preparations from, for example, fresh frozen tissue (Ferrer et al.,
2007). In addition, formalin storage length has been suggested to
affect genomic DNA yield (Wang et al., 2013; Ferrer et al., 2007), in
which the current samples were fixed for around 2 weeks (Kok
et al., 2009). We assessed the quality of prepared human DNA as an
indicator of chances for successful HSV DNA detection, assuming
that DNA degradation affects human and viral DNA equally. In fact,
samples positive for HSV DNA had a slightly higher average
129/41 bp human DNA ratio than those negative for HSV DNA,
possibly indicating that some samples are false negatives. The
indicated 1.9% of HSV-positive samples should therefore be
regarded as a minimum estimate, especially in light of earlier studies
that have focussed on AD patients in comparison with non-AD
controls. Such studies have reported a HSV prevalence ranging from
21.7-100% for non-AD individuals (Fraser et al., 1981; Bertrand
et al., 1993; Baringer and Pisani, 1994; Itzhaki et al., 1997;
Jamieson et al., 1991, 1992; Wozniak et al., 2005), although they
have generally dealt with older individuals and substantially smaller
sample sizes. Sequence variations of the infecting HSV strains
might also have resulted inmissed infections. It should also be noted
that the cohort stems from a Finnish population not previously
explored for HSV DNA.
To the authors’ knowledge, a study of this size has not previously
been performed, and it sheds light on the prevalence of HSV in brain
tissue in a unique cohort most closely representing the general
population, including individuals of all ages. The results suggest
HSV presence in brain tissue is not unusual, and further indicates
the existence of persistent or latent infections within the central
nervous system (CNS) without producing encephalitis symptoms.
The results also indicate that spread to the CNS is much more
common for HSV1 than for HSV2, consistent with a low proportion
of HSV2 being found in human brain in other studies (Lin et al.,
2002).
The small number of HSV-DNA-positive samples resulted in a
lack of power in most analyses. Although interpretation must be
made with appropriate caution, some non-significant results might
still be worth commenting on. The proportion having Aβ
aggregations among those who had HSV DNA in brain tissue (i.e.
tested positive in two or more PCR analyses) were 6/11 (54.5%)
compared with 30.2% among those who were HSV-DNA-negative
(P=0.101), 16.7% of those with AD had HSV DNA present in brain
tissue compared with 1.8% of non-demented cases (P=0.113), and
anti-HSV sero-positivity was close to being significantly associated
with an increased risk of Aβ aggregations (P=0.052). These results
are not in disagreement with previous studies suggesting that Aβ
aggregations and/or AD are associated with HSV (Ball, 1982;
Itzhaki, 2014; Itzhaki et al., 2016; Letenneur et al., 2008; Lövheim
et al., 2015a,b; Steel and Eslick, 2015), but should be confirmed in
larger studies. However, most of the individuals that had Aβ
aggregations did not have detectable HSV DNA in brain tissue.
Although this might in part be explained by the sensitivity of our
analyses, recent studies are pointing towards the Aβ reaction being a
part of the innate immune system (Itzhaki et al., 2016; Kumar et al.,
2016), with a broad antimicrobial effect against bacteria, fungi and
4 %
96 %
Aβ +ve
1 %
99 %
Aβ -ve
HSV DNA +ve HSV DNA -ve HSV DNA +ve HSV DNA -ve
Fig. 1. The prevalence of HSV DNA
positivity in cases separated by Aβ
pathology presence. Cases with HSV DNA
present are depicted in dark grey, versus
those without HSV DNA, split into groups
with and without Aβ positivity.
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viruses including HSV (Bourgade et al., 2015; Soscia et al., 2010;
White et al., 2014). Several bacteria and viruses have been
demonstrated as being able to trigger the Aβ reaction in cultured
cells and mice (Kristen et al., 2015; Little et al., 2014; Miklossy
et al., 2006; Santana et al., 2012; Shipley et al., 2005). A possible
explanation might therefore be that previous infections leave scars
in the form of Aβ aggregations; however, certain persistent
infections including HSV might continue to trigger the Aβ
production for prolonged periods of time to produce accumulation
of Aβ and ultimately Alzheimer’s disease. A number of recent
studies have leant weight to support the theory of a pathogen-
mediated AD hypothesis (Bourgade et al., 2016; Miklossy, 2011).
These include investigations into fungi (Pisa et al., 2015), bacteria
(Miklossy, 2015; Potgieter et al., 2015) and even their by-products
(Kell and Pretorius, 2015), and point towards a potential role of
several infectious pathogens in AD neurodegeneration.
Two out of three individuals positive for HSV DNA in brain
tissue with sera available were HSV sero-negative, a borderline
significantly lower proportion (P=0.053) compared with those
negative for HSV DNA, among whom 87.0% were HSV sero-
positive. Although this unexpected result must be interpreted with
caution, one possible explanation could be individuals that for some
reason have not developed a proper immune response to HSV
infection (here presented as low levels of specific antibodies), might
have an increased risk of HSV spread to the CNS. Alternatively,
sample degradation and interference with the ELISA system
resulting from post-mortem-altered blood samples could be a
source of error; however, the high prevalence of HSV sero-
positivity among those negative for HSV DNA in brain tissue
indicates a sufficient sensitivity in the ELISA analyses also for post-
mortem samples.
In conclusion, we report epidemiological evidence of HSV
presence in brain tissue from individuals who did not show
encephalitis symptoms in a cohort most closely representing the
general population (prevalence 1.9%). Six out of 11 with HSV
DNA in brain tissue had Aβ aggregations, although most of those
with Aβ aggregations did not have HSV present in brain tissue.
MATERIALS AND METHODS
Cohort and neuropathology
The TASTY cohort has been described in detail elsewhere, including Aβ
aggregation and neurofibrillary tangle (NFT) data acquisition (Kok et al.,
2009). Briefly, 603 individuals (388 males, 215 females; 64% male) aged
0-97 years (average 63 years) underwent autopsy at the Department of
Forensic Medicine, University of Tampere, Finland from 2002-2004 (see
Table 2). Samples underwent sectioning and staining with Bielschowsky
silver stain according to standardised procedures, and were measured as
positive for Aβ aggregations (n=541, 92.6% of the TASTY cohort were
tested; n=166, 30.7% were positive) and Aβ-IR (immunoreactivity) as a
percentage of area covered by Aβ aggregations (average Aβ-IR was 0.45%,
range 0-5.4%), and neurofibrillary tangle (NFT) data (data available for
n=474, 81.2%; n=199, 42.0% positive; NFT/1 mm2 average=3.4, range
0-60.8) (Kok et al., 2009). Of the 603 cases in the TASTY cohort, 31.1%
were APOEε4 carriers (n=187), 584 had brain tissue blocks and 141 had
serology samples available for the current study. Not all cases had all data
available owing to unavailable or missing samples, most often caused by
cause of death hampering sample collection.
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Fig. 2. TASTY cohort characteristics. Changes in age distribution of HSV DNA presence in brain tissue, APOEε4 carriership, Aβ aggregations, NFT, and
combined neuropathology, as well as Alzheimer’s disease cases of the TASTY cohort. Please note that only those cases with neuropathology data for both Aβ
aggregations and NFT were included in the figure.
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The autopsy series and its use were approved by the National Authority
for Medicolegal Affairs in Finland (1239/32/200/01). The Regional Ethical
Review Board in Umeå, Sweden approved the study (2013/277-31).
DNA extraction
Paraffin-embedded tissue blocks of four brain regions (middle frontal gyrus,
gyrus cingula with corpus callosum, hippocampus and cerebellum) were
sampled 4-6 times with 20-µm-thick sections and transferred into sterile
microfuge tubes. Tissue was deparaffinised according to the guidelines
outlined by Greer et al. (1994). Briefly, 1 ml xylene was added to each tube,
centrifuged at 16,000 g for 5 min, after which the supernatant was
discarded. This procedure was carried out twice. The xylene was then
removed in three washes with 99% ethanol with centrifugation at 16,000 g
for 5 min in each washing step. Tubes were left open in a dust-protected
cabinet for one hour to allow the remaining ethanol to evaporate. Thereafter,
DNA was extracted with a LIAISON Ixt pipetting/extraction instrument
fitted with a LIAISON Ixt DNA Extraction kit (Diasorin). DNA
Pretreatment Buffer 2 supplemented with Proteinase K (200 µl+10 µl was
added to each sample, and the tubes were incubated at 56°C overnight.
Samples were then centrifuged (10 min, 20,000 g) to sediment residual
material. DNAwas prepared from the digested samples and eluted into 50 µl
elution buffer.
Quality assessment of extracted DNA
The total amount and purity of DNA for each sample was assessed
by spectrophotometry (NanoDrop 1000 Full Spectrum UV/Vis
Spectrophotometer, Wilmington, USA). The total amount of DNA was
obtained in ng/μl, and the A260/280 ratio was calculated as an indicator of
protein impurities. In order to assess DNA quality with respect to
fragmentation, samples were subjected to a qPCR-based quantification of
41 bp and 129 bp targets within a conserved single-copy locus in the human
genome using a KAPA Human Genomic DNA Quantification and QC Kit
(KAPABiosystems, Cape Town, South Africa). Samples were diluted 1:100
in 10 mMTris pH 8.0+0.05% Tween 20 (DNA dilution buffer) to fall within
the dynamic range of the assay, and the qPCR reaction was performed
according to the manual for the product on an ABI StepOne Plus instrument.
Absolute quantification of 41 bp and 129 bp targets of human genomes in
samples was achieved using the standard provided in the kit.
PCR methods
PCR reactions directed against conserved regions of the HSV1 and HSV2
genomes were used to detect the respective viral DNA in the samples.
Primers and TaqMan probes were designed with the online software
Primer3Plus (Untergasser et al., 2007). Crucial design parameters were: Tm
for primers 60°C, Tm for probes 70°C, length of amplified regions 60-75 bp,
and no sequencematch to other reference genomes. Primers and probes were
ordered from EurofinsGenomics, Ebersberg, Germany, with the sequence of
primers and probes, and the size of amplicons described in Table 3. DNA
prepared from in-house HSV1 or HSV2 cultivations were used as positive
controls. DNA was diluted 1:10, after which 10 µl was added to a final
volume of 25 µl PCR mix containing TAQMAN UNIV Master MIX (Life
Technologies, Carlsbad, CA, USA), 0.3 µM of each primer and 0.2 µM
probe. Amplification reactions included an initial 15-min denaturation step
at 95°C, followed by 43 cycles of 15 s at 94°C, and 60 s at 60°C. The
reactions were performed on an ABI 7900HT instrument, and results were
analysed with the SDS software set to automatic baseline and threshold
(Automatic Ct).
Serology
Plasma collected at autopsy was stored at −80°C. Samples were thawed,
cleared of particular matters by centrifugation (10 min, 20,000 g), and
analysed for anti-HSV IgG and IgM antibodies using ELISA as described
previously (Lövheim et al., 2015a), with the exception that a new HSV1
isolate (Umeå clinical isolate 3458-13) has been introduced for antigen
production. The IgG antibody activity of the individual samples was
expressed in arbitrary units (AU), achieved by dividing the sample’s
absorbance with that of a positive reference sample, and multiplied by 100.
Samples with IgG values of 5 AU or above were regarded positive for HSV
Table 2. Characteristics of the Tampere Autopsy Study (TASTY) cohort
individuals with brain tissue samples tested for HSV DNA
HSV-DNA-negative HSV-DNA-positive P-value
Average age, years 62.6 (0-97 years) 68.1 (43-89 years) 0.413*
Brain tissue
Brain, grams 1408 (427-1910 g) 1364 (1042-1648 g) 0.620*
Sex, male 367 (64.0%) 8 (72.7%) 0.754 (FE)
BMI 27.4 (11.8-59.7) 26.9 (16.5-36.3) 0.899*
Aβ-IR, % 0.44 (0-5.4%) 0.55 (0-1.3%) 0.057*
NFT count/mm2 3.32 (0-60.8/mm2) 4.62 (0-14.4/mm2) 0.280*
Aβ aggregations 160 (30.2%) 6 (54.5%) 0.101 (FE)
NFT 194 (41.7%) 5 (55.6%) 0.502 (FE)
APOEε4 carriers 177 (31.0%) 4 (36.4%) 0.746 (FE)
Serology
HSV IgG‡ 120 (87.0%) 1 (33.3%) 0.053 (FE)
HSV IgM‡ 15 (10.9%) 0 1.000 (FE)
CoD 0.800 (FE)
Disease 320 (56.0%) 8 (72.7%)
Accident 169 (29.6%) 2 (18.2%)
Suicide 70 (12.3%) 1 (9.1%)
Homicide 3 (0.5%) 0
Unknown 9 (1.6%) 0
BMI, body mass index; CoD, cause of death; IgG, immunoglobulin G sero-
positivity for HSV; IgM, immunoglobulin M sero-positivity for HSV; FE, Fisher’s
exact test
*Mann–Whitney test
‡This data was only available for a subset of cases of the TASTY cohort
Table 3. PCR reactions used in this study against HSV DNA
Forward primer Reverse primer Probe
Amplicon
length Reference
HSV1
Reaction 1 (US5) GGCCTGGCTATCCGGAGA GCGCAGAGACATCGCGA FAM–CAGCACACGACTTGGCGT
TCTGTGT–TAMRA
63 bp Filen et al.,
2004
Reaction 2 (UL5) GCAGATGAGGTACGTGAGCA GACCTTCGAGCACCAGAAAC FAM–GTTCTCGCTCTGGCGGACGG
AAC–TAMRA
70 bp This study
Reaction 3 (UL27) GCGCTGTATGTGGTTGTACG TCAAGACCACCTCCTCCATC FAM–TAAACTGCAGCCGGGCGAAC
TC–TAMRA
62 bp This study
HSV2
Reaction 1 (US4) AGATATCCTCTTTATCATC
AGCACCA
TTGTGCTGCCAAGGCGA FAM–CAGACAAACGAACGCCGC
CG–TAMRA
73 bp Filen et al.,
2004
Reaction 2 (UL5) AACCCAAACACCATCTTTCG TCACGTACGTCCTCAACAGC FAM–CGCGGTCACCGCGACC
TG–TAMRA
64 bp This study
Reaction 3 (UL29) CACCAGCTGCTTGATGTTGT GGGAGGCTGGAGACGATTAT FAM–ACCACCGTGTGCAGGGCC
TC–TAMRA
72 bp This study
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IgG antibody content. IgM ELISA results were dichotomously determined
positive or negative with the cut-off value set at net absorbance ≥0.15.
Statistics
SPSS for Windows (version 23; IBM) was utilised in statistical analyses.
Variables used were Aβ aggregations (present yes/no; Aβ-IR %), NFT (yes/
no, NFT count), APOEε4 allele carriership (yes/no), sex, HSV DNA
positivity (two positive tests/no), anti-HSV IgG (present yes/no; AU), and
anti-HSV IgM (present yes/no).
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the Swedish Alzheimer Fund, Gun och Bertil Stohnes Stiftelse (Stohne Foundation),
Magnus Bergvalls Stiftelse (Bergvall Foundation) and Umeå Universitet Foundation
for Medical Research. These funding sources had no involvement in the study
design; collection, analysis and interpretation of data; writing of the report; or the
decision to submit this article for publication.
References
Ball, M. J. (1982). Limbic predilection in Alzheimer dementia: is reactivated
herpesvirus involved? Can. J. Neurol. Sci. 9, 303-306.
Baringer, J. R. and Pisani, P. (1994). Herpes simplex virus genomes in human
nervous system tissue analyzed by polymerase chain reaction. Ann. Neurol. 36,
823-829.
Bertrand, P., Guillaume, D., Hellauer, L., Dea, D., Lindsay, J., Kogan, S.,
Gauthier, S. and Poirier, J. (1993). Distribution of herpes simplex virus type 1
DNA in selected areas of normal and Alzheimer’s disease brains: a PCR study.
Neurodegeneration 2, 201-208.
Bhattacharjee, P. S., Neumann, D. M., Foster, T. P., Bouhanik, S., Clement, C.,
Vinay, D., Thompson, H. W. and Hill, J. M. (2008). Effect of human
apolipoprotein E genotype on the pathogenesis of experimental ocular HSV-1.
Exp. Eye Res. 87, 122-130.
Bourgade, K., Garneau, H., Giroux, G., Le Page, A. Y., Bocti, C., Dupuis, G.,
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